Annual ReportHealthcare

Ipca Laboratories Limited

IPCALAB.NS · Period ending 2026-03-31 · Filed 2026-03-31 · Updated

In short

Ipca Laboratories Limited (IPCALAB.NS) has revenue up 8.0% to INR 95.6B and net income up 54.7% to INR 11.4B year on year. Its net margin is 11.9% and gross margin 68.8%, and it trades at 37.4× trailing earnings. Fisclear found no medium- or high-severity risk flags in this filing. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

₹1,915.40

Market Cap

₹485.9B

P/E (TTM)

37.1x

Price ÷ earnings per share

P/B

6.0x

Price ÷ book value

P/S (TTM)

4.8x

Price ÷ revenue per share

Beta

0.04

Low volatility vs market

52-Week Range

₹1,251.60₹1,915.40 now₹2,038.00

4-engine score — Quality and Peers engines require SEC EDGAR (US stocks only)

Efficiency
56/100
Value
40/100
Cashflow
50/100
Regime
55/100

Based on filing period ending Mar 2026

International FisclearScore uses 4 engines (no EDGAR data). Based on Yahoo Finance & Alpha Vantage reported financials. Not financial advice.

IPCALAB.NS vs

🇮🇳 India Macro Indicators

Full dashboard →

Policy Rate

6.75%↑

Restrictive

USD/INR

95.449→

The India central bank policy rate stands at 6.75% — a restrictive rate environment; USD/INR is at 95.449.

SWOT Analysis — IPCALAB.NS

Inflationary Boom
✦

Strengths

  • Net Income: INR 11.4B (+54.7% YoY) — Profit grew 55% — the company kept more of each dollar earned.

  • EPS (Diluted): INR 44.98 (+54.7% YoY) — Earnings per share rose 55% — each share earned more.

  • Gross Profit: INR 65.8B (+11.1% YoY) — Gross profit rose 11% — the spread between revenue and direct costs improved.

  • Revenue: INR 95.6B (+8.0% YoY) — Revenue grew 8% — the company sold more goods or services than the prior year.

◈

Weaknesses

  • Operating Cash Flow: INR 11.4B (-13.6% YoY) — Operating cash flow fell 14% but remained positive.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

No significant threats flagged.

Financial Charts

Revenue vs Net Income

Gross Profit vs Operating Income

Margin Trend

Year-over-Year Changes

Net Income

INR 11.4B

was INR 7.4B

+54.7%

Profit grew 55% — the company kept more of each dollar earned.

EPS (Diluted)

INR 44.98

was INR 29.08

+54.7%

Earnings per share rose 55% — each share earned more.

Operating Cash Flow

INR 11.4B

was INR 13.2B

−13.6%

Operating cash flow fell 14% but remained positive.

Gross Profit

INR 65.8B

was INR 59.2B

+11.1%

Gross profit rose 11% — the spread between revenue and direct costs improved.

Revenue

INR 95.6B

was INR 88.5B

+8.0%

Revenue grew 8% — the company sold more goods or services than the prior year.

Price HistoryINR

Technical Signals

Daily closes · 1-year data

Latest News

via Finnhub

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Research Ipca Laboratories Limited

Data sourced from NSE India, FRED (Federal Reserve), OECD, BIS, and Yahoo Finance. For informational purposes only. Not financial advice.